Short Running Head Obesity in Rectal Cancer Patients
Body Mass Index Role in the Oncological Outcome of Locally Advanced Rectal Cancer: The Two BMI Extremes as Comparative Groups, A Retrospective Study
1 other identifier
observational
294
1 country
1
Brief Summary
There is a controversy regarding the effect of the two Body Mass Index (BMI) extremes on the oncological outcome of rectal cancer. The obesity paradox appears to exist in rectal cancer patients treated with nCRT and surgery, as it was associated with significantly higher rates of pathological complete response and R0 resection. Underweight patients were at higher risk for anastomotic leak and R1 resection.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2017
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 21, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 25, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
March 25, 2020
CompletedFirst Submitted
Initial submission to the registry
February 8, 2021
CompletedFirst Posted
Study publicly available on registry
February 18, 2021
CompletedFebruary 18, 2021
February 1, 2021
3 years
February 8, 2021
February 14, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Disease-Free Survival (DFS)
Disease-free survival (DFS) was defined as the time from surgical resection to disease recurrence (including loco-regional failure or metastases) or death of any cause
5 yers
Overall Survival (OS)
Overall survival (OS) was defined as the time interval from surgical resection to either death from any cause or last follow up
5 years
Secondary Outcomes (1)
Pathological Complete Response (CR)
5 years
Study Arms (1)
Rectal Cancer
Rectal Cancer
Eligibility Criteria
294 patients included in the study
You may qualify if:
- Patients who underwent rectal surgery at King Hussein Cancer Center (KHCC) from 2006 to 2018 were identified. Those with locally advanced rectal cancer (stages II and III) who underwent nCRT followed by surgery with curative intent were included.
You may not qualify if:
- Patients with early rectal cancer (stage I) who did not require nCRT and those who underwent rectal surgery as part of a staged or simultaneous approach for metastatic disease (stage IV) were excluded.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
King Hussein Cancer Center
Amman, 11941, Jordan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Chairman, Department of Surgery
Study Record Dates
First Submitted
February 8, 2021
First Posted
February 18, 2021
Study Start
March 21, 2017
Primary Completion
March 25, 2020
Study Completion
March 25, 2020
Last Updated
February 18, 2021
Record last verified: 2021-02
Data Sharing
- IPD Sharing
- Will not share